More questions than answers with esketamine, expert says
The trial that led to esketamine's FDA registration has just been published
A leading US psychiatrist has urged caution on the use of intranasal esketamine, which was recently approved as a treatment for refractory depression by the country’s Food and Drug Administration.
Professor Alan Schatzberg, a former president of the American Psychiatric Association, lists “worrisome findings” and calls for a “concise framework for assessing the risk-benefit balance for using this formulation of ketamine”, in an editorial in the American Journal of Psychiatry.
